Amol K Narang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10421287/publications.pdf

Version: 2024-02-01

40 papers 1,271 citations

15 h-index 35 g-index

42 all docs 42 docs citations

42 times ranked 2424 citing authors

#	Article	IF	CITATIONS
1	Structured CT reporting of pancreatic ductal adenocarcinoma: impact on completeness of information and interdisciplinary communication for surgical planning. Abdominal Radiology, 2022, 47, 704-714.	1.0	4
2	Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Institution Experience and Review of the Literature. Current Oncology, 2022, 29, 308-320.	0.9	2
3	High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer. Journal of Gastrointestinal Oncology, 2022, 13, 368-379.	0.6	6
4	Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. Annals of Surgical Oncology, 2022, 29, 2456-2468.	0.7	12
5	Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial. Practical Radiation Oncology, 2022, 12, 511-523.	1.1	5
6	Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy. Radiation Oncology Journal, 2022, 40, 111-119.	0.7	6
7	Fiducial-based image-guided SBRT for pancreatic adenocarcinoma: Does inter-and intra-fraction treatment variation warrant adaptive therapy?. Radiation Oncology, 2021, 16, 53.	1.2	6
8	Longitudinal Trends of Financial Toxicity in Patients With Lung Cancer: A Prospective Cohort Study. JCO Oncology Practice, 2021, 17, e1094-e1109.	1.4	18
9	Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection. Radiation Oncology Journal, 2021, 39, 304-314.	0.7	6
10	Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy. Radiation Oncology, 2021, 16, 242.	1.2	7
11	Feasibility of Using Hydrogel Spacers for Borderline-Resectable and Locally Advanced Pancreatic Tumors. Gastroenterology, 2019, 157, 933-935.	0.6	20
12	Readmission Adversely Affects Survival in Surgical Rectal Cancer Patients. World Journal of Surgery, 2019, 43, 2506-2517.	0.8	4
13	The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas, 2019, 48, 585-589.	0.5	10
14	Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Annals of Surgery, 2019, 270, 340-347.	2.1	280
15	Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 309.e7-309.e14.	0.8	8
16	Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediateâ€risk prostate cancer at high risk of distant recurrence and cancerâ€specific mortality. Prostate, 2018, 78, 623-630.	1.2	0
17	Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. Advances in Radiation Oncology, 2018, 3, 42-51.	0.6	2
18	Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 486-489.	0.4	2

#	Article	IF	CITATIONS
19	Adjuvant Chemoradiotherapy is Associated with Improved Survival for Patients with Resected Gallbladder Carcinoma: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2018, 25, 255-264.	0.7	29
20	Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. Annals of Surgical Oncology, 2018, 25, 280-289.	0.7	31
21	Stereotactic Ablative Radiotherapy (SABR/SBRT) for Hepatocellular Carcinoma. Current Hepatology Reports, 2018, 17, 392-398.	0.4	1
22	Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. Advances in Radiation Oncology, 2018, 3, 601-610.	0.6	5
23	Neoadjuvant Short-Course Radiation Therapy for Rectal Cancer: Trends and Controversies. Current Oncology Reports, 2018, 20, 68.	1.8	4
24	Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients. Oncotarget, 2018, 9, 16427-16436.	0.8	28
25	Progressive Low-Grade Glioma: Assessment of Prognostic Importance of Histologic Reassessment and MRI Findings. World Neurosurgery, 2017, 99, 751-757.	0.7	19
26	Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer. JAMA Oncology, 2017, 3, 757.	3.4	171
27	Socioeconomic factors affect the selection of proton radiation therapy for children. Cancer, 2017, 123, 4048-4056.	2.0	46
28	A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review. Oncotarget, 2017, 8, 100942-100950.	0.8	4
29	Prevalence of Substance Use in Patients With Cancer Receiving Radiation Therapy. Clinical Journal of Oncology Nursing, 2016, 20, 397-402.	0.3	5
30	Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 94, 254-262.	0.4	31
31	Case volume and improved outcomes across cancer care. Nature Reviews Urology, 2016, 13, 186-187.	1.9	1
32	Contemporary Radiation Therapy in Combined Modality Therapy for Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 597-605.	2.3	1
33	The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 259-265.	0.6	171
34	Trends in Advance Care Planning in Patients With Cancer. JAMA Oncology, 2015, 1, 601.	3.4	110
35	Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience. Annals of Surgical Oncology, 2015, 22, 1100-1106.	0.7	32
36	The Promise of Modern Radiotherapy in Resected Pancreatic Adenocarcinoma: A Response to Bekaii-Saab et al Annals of Surgical Oncology, 2014, 21, 1064-1066.	0.7	2

#	Article	IF	CITATION
37	Accuracy of Marketing Claims by Providers of Stereotactic Radiation Therapy. Journal of Oncology Practice, 2013, 9, 57-62.	2.5	11
38	Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Practical Radiation Oncology, 2012, 2, 77-85.	1.1	28
39	Early Mortality Risk Score: Identification of Poor Outcomes Following Upfront Surgery for Resectable Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2012, 16, 753-761.	0.9	48
40	Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study. Radiation Oncology, 2011, 6, 126.	1.2	95